Atlas Trials

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Clinical trial NCT02824029 · COMPLETED

Trial details

NCT number
NCT02824029
Sponsor
Barbara Ann Karmanos Cancer Institute
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Classical Hodgkin LymphomaRecurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Start date
2016-06-01
Primary completion
2023-05-12
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.